Why Prescription Drugs Cost Less in China — and What Foreigners Actually Pay
The short answer
Two different things are being confused when people say “drugs are cheap in China.”
The first is true: Chinese-made drugs are dramatically cheaper than imported equivalents. A domestic PD-1 inhibitor costs roughly ¥39,300 per year (≈USD 5,500) in China. The imported originator — pembrolizumab — is priced at about ¥17,900 per 100 mg vial, which for a standard regimen runs past ¥280,000 per year. That is not a discount. It is a different product at a different price tier.
The second is false, and most guides get it wrong: imported drugs are not cheap in China. For at least one common oncology drug, the imported version is more expensive in China than in Indonesia — roughly three times, as it happens. If you are flying to China to buy imported medication, check the price at home first.
What is genuinely unusual about China is neither of those. It is this: since 2026, Chinese public hospitals are legally required to sell every drug at their purchase price, with zero markup, to every patient regardless of nationality. There is no “foreigner price.” That is a stronger guarantee than most countries offer, and it is the reason the domestic-drug prices above are actually reachable by a foreign self-paying patient.
What follows is the mechanism, the numbers, and — importantly — the four ways this advantage does not work the way you might assume.
Why Chinese domestic drugs are so cheap
Not one mechanism. Three, stacked.
1. Volume-based procurement (集采)
The government buys in bulk on behalf of all public hospitals and awards contracts to the lowest bidder. For drugs with several manufacturers, prices fall hard. Insulin, statins, oncology generics — the reductions are routinely 50–90%.
This is why a Chinese-made PD-1 inhibitor can be priced where it is. It is not a subsidy. It is a procurement outcome.
2. National reimbursement negotiation (医保谈判)
For patented drugs, the national healthcare security administration negotiates a price in exchange for listing on the reimbursement list. Manufacturers accept steep cuts to get volume.
The track record for PD-1 inhibitors:
| Year | Sintilimab (信迪利单抗) annual cost |
|---|---|
| Before negotiation | ¥288,000 |
| 2019 (first PD-1 onto the national list) | ¥96,000 |
| 2021 | ¥39,300 |
| 2024 range across domestic PD-1s | ¥30,000–50,000 |
Note what fell: the list price itself, not the reimbursement rate. The drug got cheaper for everyone, including people paying entirely out of pocket.
3. Zero markup (零差率) — the rule that matters most to a foreign patient
Chinese public hospitals used to add up to 15% to drug prices. That is gone. In April 2026 the State Council made it explicit and national:
国办发〔2026〕9号《关于健全药品价格形成机制的若干意见》, §3(5): “Public medical institutions shall procure all drugs through the provincial pharmaceutical procurement platform and sell them at zero markup (excluding traditional Chinese medicine decoction pieces). … Centralised-procurement selected drugs and negotiated drugs within their agreement period may not be re-priced.”
At the April 15, 2026 State Council press conference, the official from the National Healthcare Security Administration put it plainly:
“Public hospital drugs are procured through provincial platforms and, apart from TCM decoction pieces, are all sold at zero markup.”
The phrase “may not be re-priced” is the load-bearing one. It means not the hospital, not the international department, not anyone in the chain can add margin to a negotiated or bulk-procured drug.
Several provinces extend this explicitly to private and special-needs services. Hunan’s rules on premium medical service pricing state that drugs and separately billable consumables used in premium/special-needs care are subject to the same zero-markup requirement.
Practical consequence: a drug costs the same whether you are treated in the ordinary clinic or the international department. The difference in price between those two settings is in the service, not the medicine. We come back to this.
The part most guides get wrong: which drug
“China has cheap drugs” is only true for Chinese drugs. Here is the comparison that matters.
| Drug | Indonesia | China | Who is cheaper |
|---|---|---|---|
| Pembrolizumab (Keytruda), imported originator, 100 mg | ≈ USD 850 / vial (≈ Rp 14 million) | ≈ ¥17,900 / vial (≈ USD 2,520) | 🏆 Indonesia — by roughly 3× |
| Domestic PD-1 (sintilimab, tislelizumab, camrelizumab, toripalimab) | ❌ No domestic equivalent exists. All PD-1s are imported | ¥30,000–50,000 per year | 🏆 China — no comparison possible |
| CAR-T (commercial, per infusion) | ❌ No commercial product | ¥999,000–1,290,000 (newer domestic products announced at ¥200,000+; one already priced at ¥399,000) | 🏆 China or nothing |
| Proton / heavy-ion therapy (per course) | ❌ No operating centre as of 2026 | ¥198,000–295,000 (Shanghai: ¥278,000; average total stay ¥330,000) | 🏆 China or nothing |
Read that table carefully, because it changes the pitch:
- For the imported brand drug, Indonesia is cheaper. If someone is selling you a trip to China for imported Keytruda, the arithmetic probably does not work.
- China’s advantage is in drugs and therapies that do not exist in your country at all. There is no price comparison, because there is no comparator.
That is a different kind of advantage from “we’re cheaper.” It is an availability advantage. And availability advantages do not get competed away by a neighbouring country advertising a lower price.
What this means for you, concretely
Where the money actually is
Let us be blunt about scale, because this is where medical travel writing usually goes soft.
Saving USD 150 on an MRI does not justify a flight. We have said this before and we will keep saying it.
A drug that costs ¥39,300 per year in China against ¥280,000+ for the imported equivalent is a different order of magnitude. Over a treatment course that is not a rounding error — it is the difference between affording treatment and not.
The categories where the arithmetic is genuinely large:
- Oncology drugs, where a domestic equivalent exists and is on the national reimbursement list
- CAR-T, where the alternative is either no treatment or a price 3–10× higher abroad
- Proton and heavy-ion therapy, where the alternative is Japan, Singapore or Taiwan — or nothing
Where it does not work
Four limits, and they are real:
1. Not every drug is on the list. The zero-markup rule sets the price of what a hospital buys. It does not oblige any hospital to stock any particular drug. Not every hospital carries every drug, and a hospital cannot sell you what it does not have. Confirm availability, in writing, before you book anything.
2. Negotiated prices are tied to approved indications. A drug’s reimbursement listing specifies which conditions it is listed for. Whether the negotiated price applies outside those indications is a question for the specific hospital’s pharmacy, not for a website — including this one.
3. You cannot simply buy drugs and take them home. This is the one that ends most bad plans. Prescription drugs in China require a Chinese physician’s prescription. Most oncology drugs are administered intravenously in hospital. Carrying prescription medication across a border for personal use is restricted or illegal in most countries, including Indonesia and China. We do not facilitate this, and you should be wary of anyone who offers to.
4. Treatment continuity is the harder problem. A drug is not a one-off purchase. It is a regimen, monitored with bloodwork, adjusted on response. Doing cycle one in China and cycles two through eight at home requires a Chinese oncologist willing to hand over, and a home oncologist willing to continue someone else’s protocol. That handover is often the real obstacle — not the price.
The thing that actually surprised us
While checking the prices above, we found something more useful than any single number.
A foreign patient in China can be treated in the ordinary clinic at the same price a Chinese citizen pays.
This is not a loophole or a favour. It is on the books. China’s 1998 notice on abolishing dual pricing for domestic and foreign patients established uniform pricing for basic medical services, and the “national treatment” principle has been restated in the 2016 medical service pricing reform and in current policy commentary. Foreign patients may use the ordinary outpatient clinic; the international department is an option, not a requirement.
Here is where that option costs you and where it does not:
| Cost item | Can the international department mark it up? | Basis |
|---|---|---|
| Drugs | ❌ No (except TCM decoction pieces) | 国办发〔2026〕9号 — zero markup; negotiated/bulk-procured drugs may not be re-priced |
| Separately billable consumables | ❌ No | Same, plus provincial premium-service rules |
| Service — registration, consultation, bed, procedure fees, nursing | ✅ Yes, commonly 3–10× | Premium services are market-priced under the 2016 reform; capped at 10% of total service volume |
So the decision is not “cheap vs expensive.” It is:
- Want English-speaking coordination, advance scheduling, a single room, help with translated reports, direct insurance billing? Pay the international department. For a consultation and a short stay, the absolute difference is often a few hundred dollars — worth it if you need the language support.
- On a long drug regimen where the drug is the bulk of the bill? The drug costs the same either way. The service premium multiplies a smaller number, so it matters less — but it is still real money over months.
Nobody paid by hospital commission will explain this to you, because the international department is where the commission lives. We charge you a flat fee, so telling you “you don’t need the premium clinic for this part” costs us nothing. That is not a moral claim. It is just what the business model allows us to say.
We wrote the full breakdown separately: what foreigners actually pay at Chinese public hospitals.
What we do, and what we won’t
We research your specific situation and tell you what we find, including when the answer is “this doesn’t add up.”
We do not:
- Take money from hospitals, clinics or drug companies
- Recommend a specific drug or course of treatment — that is a physician’s job, and we are not physicians
- Help you buy medication to carry across a border
- Advise on whether a treatment is right for you
We do:
- Find out which hospitals actually stock a given drug, and what they charge
- Get itemised written estimates, so you can compare against a quote at home
- Work out whether the ordinary clinic or the international department is the better fit for each part of your stay
- Tell you plainly when the conclusion is that you should stay home
Our core service is a medical trip assessment — USD 250: we research your case, shortlist appropriate departments with reasoning (including why some are unsuitable), and send itemised cost estimates with sources. If the trip does not make sense, we say so and you have still got the research.
Practical checklist before you commit to anything
- Get the drug’s generic name, not the brand name. Prices are set by generic name.
- Ask the hospital, in writing: do you stock it, and at what price per unit?
- Ask: is this price the zero-markup procurement price? It should be — ask anyway.
- Ask: is my indication within the approved listing for this price?
- Ask: who monitors me between cycles, and will you provide records in English?
- Check the price of the imported version at home before assuming China is cheaper — it may not be.
- Check your own country’s import rules for any medication you plan to continue at home.
- Budget the whole course, not one cycle. Flights and accommodation multiply.
Download the full price table
We keep an updated checklist with sourcing notes on imaging, endoscopy, checkups and drugs — the same document we use ourselves. No hospital commissions, no referral fees, and it says plainly which categories China is not cheaper in.
[Get the 2026 China Medical Travel Checklist →]
Prices and policy citations current as of October 2026. Policy documents cited: 国办发〔2026〕9号《关于健全药品价格形成机制的若干意见》 (State Council, 2026-04-14); State Council Information Office policy briefing, 2026-04-15; Hunan Provincial Healthcare Security Administration notice on premium medical service pricing; 1998 notice abolishing dual pricing for domestic and foreign patients. Drug prices change and hospital formularies change. Verify everything with the treating hospital, in writing, before making any decision.